The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Chronic Reactive Arthritis Secondary to Intravesical Bacillus Calmette–Guerin in Bladder Carcinoma

Chronic Reactive Arthritis Secondary to Intravesical Bacillus Calmette–Guerin in Bladder Carcinoma

September 8, 2016 • By Derick N. Jenkins, MD, Josna Haritha, MD, & Huzaefah Syed, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Monkey Business Images/shutterstock.com

Monkey Business Images/shutterstock.com

A 50-year-old man with history of superficial bladder carcinoma presented to our rheumatology clinic for a three-year history of symmetric polyarthralgias. He had undergone multiple transurethral resection of bladder tumor procedures and bacillus Calmette–Guerin (BCG) treatments.

You Might Also Like
  • Reactive Arthritis
  • Study Assesses the Role of Genetics & the Gut in Reactive Arthritis
  • Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias
Explore This Issue
September 2016

Prior to receiving BCG, he was fully functional and employed. Days after receiving his second BCG treatment, he developed arthralgias in his fingers, hands, wrists, low back including sacroiliac joints, knees, ankles and feet, which persisted. Of all of the joints involved, his knees affected him the most. The pain was so disabling that he lost his job and a great deal of his functional ability. He also suffered from insomnia secondary to pain. He complained of a dry mouth, but had not had conjunctivitis or uveitis. He himself felt that the arthralgias were related to the BCG treatments due to the temporal relationship of receiving these and the onset of his symptoms. ANA and RF had been checked by his primary care physician previously and were negative.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

On physical examination, he had no active joint swelling, but he reported that his fingers and knees would intermittently swell and become acutely painful. He walked with a cane and had difficulty getting to the exam room unassisted. He had no active synovitis, but was tender to palpation of the bilateral MCPs, knees and right metatarsal heads. His right sacroiliac joint was tender to palpation.

Discussion

The spondyloarthropathies, including ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease-associated arthritis and reactive arthritis, are characterized by an asymmetrical oligoarthritis with non‑articular features, such as dac­tylitis, uveitis and enthesitis, as well as sacro­iliac joint and lumbar spine involvement. Reactive arthritis typically occurs after a genitourinary or gastrointestinal infection, most commonly with Chlamydia trachomatis. The typical clinical picture is an asymmetric oligoarthritis with associated conjunctivitis, urethritis and arthritis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Reactive arthritis can be difficult to distinguish from seronegative rheumatoid arthritis, but the former tends to have a predilection for joints below the waist, typically affecting knees and ankles asymmetrically; however, 50% of patients can have upper joint involvement as well. The presence of lower back pain that is worse at night with radiation to the buttocks is present in about 30% of patients with reactive arthritis. Seronegative rheumatoid arthritis typically presents with a symmetrical polyarticular involvement and has a predilection for the cervical spine rather than the lower back region.1

Reactive arthritis secondary to intra­vesical BCG is a rare, but well-recognized, condition. A systematic review by Bernini et al from October 2013 found 73 papers and 112 total patients with this condition reported in the literature worldwide. They looked at 61 of these papers and 89 of these patients, of which 73 were male and 16 female. Fifty-five percent (55.1%) of these patients had polyarthritis, and of these, 51% were symmetric; 37% had oligoarthritis, and of these, 33.3% were symmetric; 7.9% had monoarthritis; 59.6% of the total patients had an asymmetric distribution of their arthritis. The knee and ankle were the most frequently involved joints, and 42.6% were HLA-B27 positive. Over 70% (70.5%) of the patients recovered from their arthralgias within two months, and 93.2% recovered within six months. The development of a chronic form (lasting more than six months) of the arthritis was rare, occurring in 6.8% of the patients.2

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: Bacillus Calmette–Guerin, bladder, carcinoma, case report, Clinical, Diagnosis, outcome, patient care, Reactive arthritis, rheumatologist, TreatmentIssue: September 2016

You Might Also Like:
  • Reactive Arthritis
  • Study Assesses the Role of Genetics & the Gut in Reactive Arthritis
  • Diagnosis of Acute Gouty Arthritis Obscured by Anchoring Bias
  • Reactive Arthritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.